BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist (TICA) induces tumor localized CD137 agonism

Authors
Kristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, Eric Haines, Heather Cohen, Elizabeth Repash, Drasti Kanakia, Jun Ma, Julia Kristensen, Carly Campbell, David Witty, Mike Kelly, Stephen Blakemore, Phil Jeffrey, Kevin McDonnell, Philip Brandish, Nicholas Keen

Correspondence
nicholas.keen@icicite.com

In Brief
BT7480 is a highly potent Nectin-4-dependent CD137 agonist that elicits a profound reprogramming of the tumor immune microenvironment including an early and rapid myeloid cell activation that precedes upregulation of cytotoxicity-related genes. BT7480 leads to complete regressions and anti-tumor immunity with only intermittent drug exposure in syngeneic mouse tumor models. This work supports the clinical investigation of BT7480 for the treatment of cancer in humans.